A DNA Real-time Quantitative PCR Method Suitable for Routine Monitoring of Low Levels of Minimal Residual Disease in Chronic Myeloid Leukemia

The BCR-ABL1 sequence has advantages over the BCR-ABL1 transcript as a molecular marker in chronic myeloid leukemia and has been used in research studies. We developed a DNA real-time quantitative PCR (qPCR) method for quantification of BCR-ABL1 sequences, which is also potentially suitable for routine use. The BCR-ABL1 breakpoint was sequenced after isolation by nested short-range PCR of DNA from blood, marrow, and cells on slides, obtained either at diagnosis or during treatment, or from artificial mixtures.
Source: Journal of Molecular Diagnostics - Category: Pathology Authors: Tags: Regular Article Source Type: research

Related Links:

Nilotinib, a tyrosine kinase inhibitor, used for the treatment of chronic myeloid leukemia (CML), is known to produce atherosclerotic complications such as coronary artery disease, peripheral artery disease [1] and intracranial arterial stenosis/occlusion (ICASO) [2,3]. Middle cerebral artery (MCA) is the most common site involved in ICASO in CML patients treated with nilotinib [2]. It has been remained unknown what factors influence the development of ICASO in patients treated with nilotinib. Because reported patients with ICASO were rare, there is a possibility that some specific factors such as genetic mutations are ass...
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research
Publication date: Available online 7 November 2019Source: Journal of Chemical NeuroanatomyAuthor(s): Henrique J.C.B. Gouveia, Raul Manhães-de-Castro, Bárbara J.R. Costa-de-Santana, Carolina R. Mendonça, Glayciele Leandro de Albuquerque, Diego Bulcão Visco, Diego Cabral Lacerda, Ana Elisa ToscanoAbstractBusulfan is a bifunctional alkylating agent used for myeloablative conditioning and in the treatment of chronic myeloid leukemia due to its ability to cause DNA damage. However, in rodent experiments, busulfan presented a potential teratogenic and cytotoxic effect. Studies have evaluated the effec...
Source: Journal of Chemical Neuroanatomy - Category: Neuroscience Source Type: research
We report a novel case in which hydroxyurea hyperpigmentation is associated with iron deposition.
Source: Dermatology Online Journal - Category: Dermatology Source Type: research
UCLA legend and NBA Hall of Famer Kareem Abdul-Jabbar is teaming up with UCLA Health for a wide variety of new health and wellness initiatives designed to improve health and prevent disease.The partnership will be announced at the 2019 Leukemia and Lymphoma Society ’s Los Angeles Light the Night Walk, an event for which UCLA Health is the presenting sponsor.  The Los Angeles Laker superstar and UCLA Bruin basketball player is a survivor of chronic myeloid leukemia, or CML, which is a form of blood cancer. To honor his survivorship, Abdul-Jabbar has served as an ambassador and UCLA Health fundraising team ca...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
In this study, we found that miR328 significantly and strikingly decreased among other miRNA candidates during the induction of imatinib resistance. Overexpression of miR328 sensitized resistant cells to imatinib via post-transcriptionally decreasing ABCG2 expression, while miR328 knockdown conferred imatinib resistance in parental K562 cells. Moreover, miR328 was found selectively degraded in the lysosomes of K562R cells, as inhibition of lysosome with chloroquine restored miR328 expression and increased sensitivity to imatinib. Moreover, delivery of alkalized exosomes increased endogenous miR328 expression. Compared with...
Source: Applied Microbiology and Biotechnology - Category: Microbiology Authors: Tags: Appl Microbiol Biotechnol Source Type: research
AbstractPurposeIn chronic myeloid leukaemia, tyrosine kinase inhibitor treatment is traditionally given continuously for life. However, these drugs produce excellent responses for many patients, and this is accompanied by survival that is close to normal. This has prompted studies of whether it is possible to stop treatment, thus achieving a treatment-free remission (TFR).Recent FindingsMost TFR studies have focussed on abrupt cessation in patients with long-standing deep remissions, but recent data suggest that more gradual treatment de-escalation may improve TFR success, and that it may be possible to extend TFR attempts...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
AbstractPurpose of ReviewThe marked improvement in clinical outcomes for patients with chronic myeloid leukaemia (CML) can be solely attributed to the introduction of targeted therapies against the fusion oncoprotein,BCR-ABL1. However, patient responses, although generally positive, remain heterogenous. Careful drug selection, ensuring the optimal TKI, is chosen for each patient and involves a complex decision process which incorporates consideration of numerous factors.Recent FindingsFor some patients, with disease characteristics that indicate adverse intrinsic disease biology, more potentBCR-ABL1 inhibition is often app...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
AbstractPurpose of ReviewIdentification of theBCR-ABL1 fusion oncogene in patients diagnosed with chronic myeloid leukemia (CML) led to the development of targeted therapy responsible for the dramatic survival benefits observed in the past two decades. However, despite these revolutionary findings, there remains marked disparity in patient outcomes. Why do some patients present de novo while others evolve to the more aggressive stages of CML? Why can select patients successfully discontinue therapy as part of a treatment-free remission attempt whereas others fail to meet specific molecular milestones?Recent FindingsBCR-ABL...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
Condition:   Chronic Myelocytic Leukemia Intervention:   Other: RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis Sponsors:   Seoul St. Mary's Hospital;   Bristol-Myers Squibb Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 2 November 2019Source: Chemico-Biological InteractionsAuthor(s): Hyllana C.D. Medeiros, Carina Colturato-Kido, Letícia S. Ferraz, Claudia A. Costa, Vivian W.R. Moraes, Edgar Julian Paredes-Gamero, Ivarne L.S. Tersariol, Tiago RodriguesAbstractRelapse and drug resistance is still major challenges in the treatment of leukemia. Promethazine, an antihistaminic phenothiazine derivative, has been used to prevent chemotherapy-induced emesis, although there is no report about its antitumor potential. Thus, we evaluated the promethazine cytotoxicity against several leukemia cells and the un...
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Leukemia | Pathology | Study